The Advancements in Melanoma Treatment - Interactive

Register

Melanoma is the fifth most commonly diagnosed cancer in the U.S. Before 2011, treatment options for individuals diagnosed with advanced melanoma were limited with a five-year overall survival rate of approximately 10%. Since 2011, significant progress has been made with FDA approval of nearly 20 treatment options resulting in a five-year overall survival rate of more than 50%. This presentation will focus on recent updates for treating advanced melanoma.

Learning Objectives

At the conclusion of this activity, participants should be able to:

  • Describe the role of neoadjuvant therapy in resectable clinical stage III and oligometastatic stage IV melanoma
  • Summarize the data regarding sequencing of immunotherapy and targeted therapy in BRAFV600E/K mutated advanced melanoma
  • Explain the evolving landscape in treatment of metastatic melanoma

AAPA offers no returns or refunds for online CME activities purchased via the AAPA store. All sales are final.
Register